קובאלטרי iu 2000
bayer israel ltd - recombinant human coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - recombinant human coagulation factor viii 2000 iu - coagulation factor viii
קובאלטרי iu 250
bayer israel ltd - recombinant human coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - recombinant human coagulation factor viii 250 iu - coagulation factor viii
קובאלטרי iu 500
bayer israel ltd - recombinant human coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - recombinant human coagulation factor viii 500 iu - coagulation factor viii
קימריה
novartis israel ltd - tisagenlecleucel - tisagenlecleucel
בינוקריט 8000 יחבל 0.8 מל
novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 8000 iu / 0.8 ml - erythropoietin
טאלץ 80 מג
eli lilly israel ltd, israel - ixekizumab - תמיסה להזרקה - ixekizumab 80 mg / 1 ml - ixekizumab
צטרימיד שמפו ויטאמד
vitamed pharmaceutical industries ltd - cetrimide - שמפו - cetrimide 10 % - cetrimide - cetrimide - for the treatment of dandruff.
סנדאימון ניאורל 50 מג כמוסות
novartis israel ltd - ciclosporin - קפסולות - ciclosporin 50 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.
סנדאימון ניאורל 100 מג כמוסות
novartis israel ltd - ciclosporin - קפסולות - ciclosporin 100 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.
וילאט 1000
dover medical & scientific equipment ltd, israel - factor viii (human); von willebrand factor - אבקה וממס להכנת תמיסה להזרקה - von willebrand factor 1000 iu/vial; factor viii (human) 1000 iu/vial - coagulation factor viii